<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?>
<document xmlns:voc="http://www.hl7.org/v3/voc" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
	<id root="F0EFE507-97CF-4DFC-E890-B542B69549F3"/>
	<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Human prescription drug label"/>
	<title mediaType="text/x-hl7-title+xml">MANNITOL I.V.<br/>MANNITOL Injection, USP</title>
	<effectiveTime value="20060608"/>
	<setId root="F0EFE507-97CF-4DFC-E890-B542B69549F3"/>
	<versionNumber value="1"/>
	<author>
		<time/>
		<assignedEntity>
			<representedOrganization>
				<name>Hospira, Inc.</name>
			</representedOrganization>
		</assignedEntity>
	</author>
	<component>
		<structuredBody>
			<component>
				<section>
					<id root="71F73616-A1DC-9CB2-CDA7-E47DFD923B31"/>
					<effectiveTime value="20060608"/>
					<subject>
						<manufacturedProduct>
							<manufacturedMedicine>
								<code code="0409-7712" codeSystem="2.16.840.1.113883.6.69"/>
								<name>Mannitol</name>
								<formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
								<activeIngredient>
									<quantity>
										<numerator unit="g" value="5">
											<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="5"/>
										</numerator>
										<denominator unit="mL" value="100">
											<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100"/>
										</denominator>
									</quantity>
									<activeIngredientSubstance>
										<code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>mannitol</name>
										<activeMoiety>
											<activeMoiety>
												<code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
												<name>mannitol</name>
											</activeMoiety>
										</activeMoiety>
									</activeIngredientSubstance>
								</activeIngredient>
								<asEntityWithGeneric>
									<genericMedicine>
										<name>Mannitol</name>
									</genericMedicine>
								</asEntityWithGeneric>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="8MDF5V39QO" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>sodium bicarbonate</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>Water</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<asContent>
									<quantity>
										<numerator unit="mL" value="1000">
											<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="1000"/>
										</numerator>
										<denominator value="1">
											<translation value="1"/>
										</denominator>
									</quantity>
									<containerPackagedMedicine>
										<code/>
										<formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
										<asContent>
											<quantity>
												<numerator value="12">
													<translation code="C48474" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG" value="12"/>
												</numerator>
												<denominator value="1">
													<translation value="1"/>
												</denominator>
											</quantity>
											<containerPackagedMedicine>
												<code code="0409-7712-09" codeSystem="2.16.840.1.113883.6.69"/>
												<formCode code="C43184" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CASE"/>
											</containerPackagedMedicine>
										</asContent>
									</containerPackagedMedicine>
								</asContent>
							</manufacturedMedicine>
							<consumedIn>
								<substanceAdministration>
									<routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
								</substanceAdministration>
							</consumedIn>
						</manufacturedProduct>
					</subject>
					<subject>
						<manufacturedProduct>
							<manufacturedMedicine>
								<code code="0409-7713" codeSystem="2.16.840.1.113883.6.69"/>
								<name>Mannitol</name>
								<formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
								<activeIngredient>
									<quantity>
										<numerator unit="g" value="10">
											<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="10"/>
										</numerator>
										<denominator unit="mL" value="100">
											<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100"/>
										</denominator>
									</quantity>
									<activeIngredientSubstance>
										<code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>mannitol</name>
										<activeMoiety>
											<activeMoiety>
												<code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
												<name>mannitol</name>
											</activeMoiety>
										</activeMoiety>
									</activeIngredientSubstance>
								</activeIngredient>
								<asEntityWithGeneric>
									<genericMedicine>
										<name>Mannitol</name>
									</genericMedicine>
								</asEntityWithGeneric>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="8MDF5V39QO" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>sodium bicarbonate</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>Water for Injection, USP</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<asContent>
									<quantity>
										<numerator unit="mL" value="1000">
											<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="1000"/>
										</numerator>
										<denominator value="1">
											<translation value="1"/>
										</denominator>
									</quantity>
									<containerPackagedMedicine>
										<code/>
										<formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
										<asContent>
											<quantity>
												<numerator value="12">
													<translation code="C48474" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG" value="12"/>
												</numerator>
												<denominator value="1">
													<translation value="1"/>
												</denominator>
											</quantity>
											<containerPackagedMedicine>
												<code code="0409-7713-09" codeSystem="2.16.840.1.113883.6.69"/>
												<formCode code="C43184" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CASE"/>
											</containerPackagedMedicine>
										</asContent>
									</containerPackagedMedicine>
								</asContent>
							</manufacturedMedicine>
							<consumedIn>
								<substanceAdministration>
									<routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
								</substanceAdministration>
							</consumedIn>
						</manufacturedProduct>
					</subject>
					<subject>
						<manufacturedProduct>
							<manufacturedMedicine>
								<code code="0409-7714" codeSystem="2.16.840.1.113883.6.69"/>
								<name>Mannitol</name>
								<formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
								<activeIngredient>
									<quantity>
										<numerator unit="g" value="15">
											<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="15"/>
										</numerator>
										<denominator unit="mL" value="100">
											<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100"/>
										</denominator>
									</quantity>
									<activeIngredientSubstance>
										<code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>mannitol</name>
										<activeMoiety>
											<activeMoiety>
												<code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
												<name>mannitol</name>
											</activeMoiety>
										</activeMoiety>
									</activeIngredientSubstance>
								</activeIngredient>
								<asEntityWithGeneric>
									<genericMedicine>
										<name>Mannitol</name>
									</genericMedicine>
								</asEntityWithGeneric>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="8MDF5V39QO" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>sodium bicarbonate</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>Water</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<asContent>
									<quantity>
										<numerator unit="mg" value="500">
											<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="500"/>
										</numerator>
										<denominator value="1">
											<translation value="1"/>
										</denominator>
									</quantity>
									<containerPackagedMedicine>
										<code/>
										<formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
										<asContent>
											<quantity>
												<numerator value="12">
													<translation code="C48474" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG" value="12"/>
												</numerator>
												<denominator value="1">
													<translation value="1"/>
												</denominator>
											</quantity>
											<containerPackagedMedicine>
												<code code="0409-7714-03" codeSystem="2.16.840.1.113883.6.69"/>
												<formCode code="C43184" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CASE"/>
											</containerPackagedMedicine>
										</asContent>
									</containerPackagedMedicine>
								</asContent>
							</manufacturedMedicine>
							<consumedIn>
								<substanceAdministration>
									<routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
								</substanceAdministration>
							</consumedIn>
						</manufacturedProduct>
					</subject>
					<subject>
						<manufacturedProduct>
							<manufacturedMedicine>
								<code code="0409-7715" codeSystem="2.16.840.1.113883.6.69"/>
								<name>Mannitol</name>
								<formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
								<activeIngredient>
									<quantity>
										<numerator unit="g" value="20">
											<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="20"/>
										</numerator>
										<denominator unit="mL" value="100">
											<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100"/>
										</denominator>
									</quantity>
									<activeIngredientSubstance>
										<code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>mannitol</name>
										<activeMoiety>
											<activeMoiety>
												<code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
												<name>mannitol</name>
											</activeMoiety>
										</activeMoiety>
									</activeIngredientSubstance>
								</activeIngredient>
								<asEntityWithGeneric>
									<genericMedicine>
										<name>Mannitol</name>
									</genericMedicine>
								</asEntityWithGeneric>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="8MDF5V39QO" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>sodium bicarbonate</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>Water</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<asContent>
									<quantity>
										<numerator unit="mL" value="250">
											<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="250"/>
										</numerator>
										<denominator value="1">
											<translation value="1"/>
										</denominator>
									</quantity>
									<containerPackagedMedicine>
										<code/>
										<formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
										<asContent>
											<quantity>
												<numerator value="24">
													<translation code="C48474" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG" value="24"/>
												</numerator>
												<denominator value="1">
													<translation value="1"/>
												</denominator>
											</quantity>
											<containerPackagedMedicine>
												<code code="0409-7715-02" codeSystem="2.16.840.1.113883.6.69"/>
												<formCode code="C43184" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CASE"/>
											</containerPackagedMedicine>
										</asContent>
									</containerPackagedMedicine>
								</asContent>
								<asContent>
									<quantity>
										<numerator unit="mL" value="500">
											<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="500"/>
										</numerator>
										<denominator value="1">
											<translation value="1"/>
										</denominator>
									</quantity>
									<containerPackagedMedicine>
										<code/>
										<formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
										<asContent>
											<quantity>
												<numerator value="12">
													<translation code="C48474" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG" value="12"/>
												</numerator>
												<denominator value="1">
													<translation value="1"/>
												</denominator>
											</quantity>
											<containerPackagedMedicine>
												<code code="0409-7715-03" codeSystem="2.16.840.1.113883.6.69"/>
												<formCode code="C43184" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CASE"/>
											</containerPackagedMedicine>
										</asContent>
									</containerPackagedMedicine>
								</asContent>
							</manufacturedMedicine>
							<consumedIn>
								<substanceAdministration>
									<routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
								</substanceAdministration>
							</consumedIn>
						</manufacturedProduct>
					</subject>
					<subject>
						<manufacturedProduct>
							<manufacturedMedicine>
								<code code="0409-4031" codeSystem="2.16.840.1.113883.6.69"/>
								<name>Mannitol</name>
								<formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
								<activeIngredient>
									<quantity>
										<numerator unit="g" value="25">
											<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="25"/>
										</numerator>
										<denominator unit="mL" value="100">
											<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100"/>
										</denominator>
									</quantity>
									<activeIngredientSubstance>
										<code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>mannitol</name>
										<activeMoiety>
											<activeMoiety>
												<code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
												<name>mannitol</name>
											</activeMoiety>
										</activeMoiety>
									</activeIngredientSubstance>
								</activeIngredient>
								<asEntityWithGeneric>
									<genericMedicine>
										<name>Mannitol</name>
									</genericMedicine>
								</asEntityWithGeneric>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="8MDF5V39QO" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>sodium bicarbonate</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>hydrochloric acid</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>Water</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<asContent>
									<quantity>
										<numerator unit="mL" value="50">
											<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="50"/>
										</numerator>
										<denominator value="1">
											<translation value="1"/>
										</denominator>
									</quantity>
									<containerPackagedMedicine>
										<code/>
										<formCode code="C43209" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, GLASS"/>
										<asContent>
											<quantity>
												<numerator value="25">
													<translation code="C48551" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL" value="25"/>
												</numerator>
												<denominator value="1">
													<translation value="1"/>
												</denominator>
											</quantity>
											<containerPackagedMedicine>
												<code code="0409-4031-01" codeSystem="2.16.840.1.113883.6.69"/>
												<formCode code="C43184" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CASE"/>
											</containerPackagedMedicine>
										</asContent>
									</containerPackagedMedicine>
								</asContent>
							</manufacturedMedicine>
							<consumedIn>
								<substanceAdministration>
									<routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
								</substanceAdministration>
							</consumedIn>
						</manufacturedProduct>
					</subject>
				</section>
			</component>
			<component>
				<section>
					<id root="6F4E93A1-DB0E-4790-F5AB-EEECA3C3C705"/>
					<code/>
					<title mediaType="text/x-hl7-title+xml"/>
					<text>
						<paragraph>Flexible Plastic Container</paragraph>
						<paragraph>Fliptop
Vial</paragraph>
						<paragraph>R<sub>x</sub> only</paragraph>
					</text>
					<effectiveTime value="20060608"/>
				</section>
			</component>
			<component>
				<section>
					<id root="F3CBC584-6455-9D9A-8F45-B40E6E1C9C23"/>
					<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DESCRIPTION SECTION"/>
					<title mediaType="text/x-hl7-title+xml">DESCRIPTION</title>
					<text>
						<paragraph>Mannitol I.V. (Mannitol Injection, USP) is a sterile, nonpyrogenic
solution of mannitol in water for injection available in concentrations of
5%, 10%, 15%, 20% in flexible plastic containers and 25% in a Fliptop vial
for administration by intravenous infusion only.</paragraph>
						<paragraph>The
content and characteristics of the available concentrations are as follows:</paragraph>
						<paragraph/>
						<table frame="below">
							<caption/>
							<colgroup>
								<col/>
								<col/>
								<col/>
								<col/>
							</colgroup>
							<tbody>
								<tr>
									<td valign="top"/>
									<td valign="top"/>
									<td align="center" valign="top">
										<paragraph>
											<content styleCode="bold">mOsmol/liter</content>
										</paragraph>
									</td>
									<td valign="top"/>
								</tr>
								<tr>
									<td align="center" valign="top">
										<paragraph>
											<content styleCode="bold">Conc.
(%)</content>
										</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>
											<content styleCode="bold">g/100
mL</content>
										</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>
											<content styleCode="bold">(calc.)</content>
										</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>
											<content styleCode="bold">pH*</content>
										</paragraph>
									</td>
								</tr>
								<tr>
									<td align="center" valign="top">
										<paragraph>5</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>5</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>274</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>6.3 (4.5 to 7.0)</paragraph>
									</td>
								</tr>
								<tr>
									<td align="center" valign="top">
										<paragraph>10</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>10</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>549</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>6.3 (4.5 to 7.0)</paragraph>
									</td>
								</tr>
								<tr>
									<td align="center" valign="top">
										<paragraph>15</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>15</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>823</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>6.3 (4.5 to 7.0)</paragraph>
									</td>
								</tr>
								<tr>
									<td align="center" valign="top">
										<paragraph>20</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>20</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>1098</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>6.3 (4.5 to 7.0)</paragraph>
									</td>
								</tr>
								<tr>
									<td align="center" valign="top">
										<paragraph>25</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>25</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>1372</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>5.9 (4.5 to 7.0)</paragraph>
									</td>
								</tr>
							</tbody>
						</table>
						<paragraph>*Concentrations up to 20% may contain sodium bicarbonate
for pH adjustment; the 25% concentration may contain sodium bicarbonate and/or
hydrochloric acid for pH adjustment.</paragraph>
						<paragraph>The solutions contain
no bacteriostat, antimicrobial agent or added buffer (except for pH adjustment)
and each is intended only as a single-dose injection. When smaller doses are
required the unused portion should be discarded.</paragraph>
						<paragraph>Mannitol
Injection, USP is a parenteral obligatory osmotic diuretic.</paragraph>
						<paragraph>Mannitol,
USP is chemically designated D-mannitol (C<sub>6</sub>H<sub>14</sub>O<sub>6</sub>),
a white crystalline powder or free-flowing granules freely soluble in water.
It has the following structural formula:</paragraph>
						<paragraph>
							<renderMultiMedia referencedObject="MM1136298161-1"/>
						</paragraph>
						<paragraph>Water
for Injection, USP is chemically designated H<sub>2</sub>0.</paragraph>
						<paragraph>The
flexible plastic container is fabricated from a specially formulated polyvinylchloride.
Water can permeate from inside the container into the overwrap, but not in
amounts sufficient to affect the solution significantly. Solutions in contact
with the plastic container may leach out certain chemical components from
the plastic in very small amounts; however, biological testing was supportive
of the safety of the plastic container materials. Exposure to temperatures
above 25&#176;C/77&#176;F during transport and storage will lead to minor
losses in moisture content. Higher temperatures lead to greater losses. It
is unlikely that these minor losses will lead to clinically significant changes
within the expiration period.</paragraph>
					</text>
					<effectiveTime value="20060608"/>
					<component>
						<observationMedia ID="MM1136298161-1">
							<id root="714F38DF-570B-4D71-06A7-1470D0A34BB5"/>
							<value mediaType="image/jpeg" xsi:type="ED">
								<reference value="xen-0074-1.jpg"/>
							</value>
						</observationMedia>
					</component>
				</section>
			</component>
			<component>
				<section>
					<id root="563B3406-DF30-C270-A340-FF0569516FE3"/>
					<code code="34090-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CLINICAL PHARMACOLOGY SECTION"/>
					<title mediaType="text/x-hl7-title+xml">CLINICAL PHARMACOLOGY</title>
					<text>
						<paragraph>When administered intravenously mannitol is confined to the
extracellular space, only slightly metabolized and rapidly excreted by the
kidney. Approximately 80% of a 100 g dose appears in the urine in 3 hours.
The drug is freely filtered by the glomeruli with less than 10% tubular reabsorption;
it is not secreted by tubular cells. Mannitol induces diuresis by elevating
the osmolarity of the glomerular filtrate and thereby hindering tubular reabsorption
of water. Excretion of sodium and chloride is also enhanced.</paragraph>
					</text>
					<effectiveTime value="20060608"/>
				</section>
			</component>
			<component>
				<section>
					<id root="1DF1621F-EB3A-ED20-4DDD-D7E55790F64E"/>
					<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="INDICATIONS &amp; USAGE SECTION"/>
					<title mediaType="text/x-hl7-title+xml">INDICATIONS AND USAGE</title>
					<text>
						<paragraph>Mannitol I.V. (Mannitol Injection, USP) is indicated for
the following purposes in adults and pediatric patients.</paragraph>
						<paragraph>
							<content styleCode="bold">Therapeutic Use</content>
						</paragraph>
						<list listType="ordered">
							<item>
								<paragraph>Promotion of diuresis in the prevention or treatment of the
oliguric phase of acute renal failure before irreversible renal failure becomes
established.</paragraph>
							</item>
							<item>
								<paragraph>Reduction of intracranial pressure and brain mass.</paragraph>
							</item>
							<item>
								<paragraph>Reduction of high intraocular pressure when the pressure
cannot be lowered by other means.</paragraph>
							</item>
							<item>
								<paragraph>Promotion of urinary excretion of toxic materials.</paragraph>
							</item>
						</list>
						<paragraph>
							<content styleCode="bold">Diagnostic Use</content>
						</paragraph>
						<paragraph>Measurement
of glomerular filtration rate.</paragraph>
					</text>
					<effectiveTime value="20060608"/>
				</section>
			</component>
			<component>
				<section>
					<id root="5959A06F-E0EA-D086-2FA7-6F3BE7DE40D2"/>
					<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CONTRAINDICATIONS SECTION"/>
					<title mediaType="text/x-hl7-title+xml">CONTRAINDICATIONS</title>
					<text>
						<list listType="ordered">
							<item>
								<paragraph>Well established anuria due to severe renal disease.</paragraph>
							</item>
							<item>
								<paragraph>Severe pulmonary congestion or frank pulmonary edema.</paragraph>
							</item>
							<item>
								<paragraph>Active intracranial bleeding except during craniotomy.</paragraph>
							</item>
							<item>
								<paragraph>Severe dehydration.</paragraph>
							</item>
							<item>
								<paragraph>Progressive renal damage or dysfunction after institution
of mannitol therapy, including increasing oliguria and azotemia.</paragraph>
							</item>
							<item>
								<paragraph>Progressive heart failure or pulmonary congestion after institution
of mannitol therapy.</paragraph>
							</item>
							<item>
								<paragraph>Do not administer to patients with a known hypersensitivity
to mannitol.</paragraph>
							</item>
						</list>
					</text>
					<effectiveTime value="20060608"/>
				</section>
			</component>
			<component>
				<section>
					<id root="05171AD8-7ECA-9FFB-D98E-29C0A9B6D0E6"/>
					<code code="34071-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="WARNINGS SECTION"/>
					<title mediaType="text/x-hl7-title+xml">WARNINGS</title>
					<text>
						<list listType="ordered">
							<item>
								<paragraph>In patients with severe impairment of renal function, a test
dose should be utilized (see DOSAGE AND ADMINISTRATION). A second test dose
may be tried if there is an inadequate response, but no more than two test
doses should be attempted.</paragraph>
							</item>
							<item>
								<paragraph>The obligatory diuretic response following rapid infusion
of 25% mannitol may further aggravate pre-existing hemoconcentration. Excessive
loss of water and electrolytes may lead to serious imbalances. Serum sodium
and potassium should be carefully monitored during mannitol administration.</paragraph>
							</item>
							<item>
								<paragraph>If urine output continues to decline during mannitol infusion,
the patient&#8217;s clinical status should be closely reviewed and mannitol
infusion suspended if necessary. Accumulation of mannitol may result in overexpansion
of the extracellular fluid which may intensify existing or latent congestive
heart failure.</paragraph>
							</item>
							<item>
								<paragraph>Excessive loss of water and electrolytes may lead to serious
imbalances. With continued administration of mannitol, loss of water in excess
of electrolytes can cause hypernatremia. Electrolyte measurements, including
sodium and potassium are therefore of vital importance in monitoring the infusion
of mannitol.</paragraph>
							</item>
							<item>
								<paragraph>Osmotic nephrosis, a reversible vacuolization of the tubules
of no known clinical significance, may proceed to severe irreversible nephrosis,
so that the renal function must be closely monitored during mannitol infusion.</paragraph>
							</item>
							<item>
								<paragraph>Mannitol injection may increase cerebral blood flow and the
risk of postoperative bleeding in neurosurgical patients.</paragraph>
							</item>
							<item>
								<paragraph>For intravenous use only. Do not administer intramuscularly
or subcutaneously. Never add mannitol in whole blood for transfusion.</paragraph>
							</item>
							<item>
								<paragraph>Mannitol may increase the cerebral blood flow and worsen
intracranial hypertension in children who develop a generalized cerebral hyperemia
during the first 24 to 48 hours post injury.</paragraph>
							</item>
						</list>
					</text>
					<effectiveTime value="20060608"/>
				</section>
			</component>
			<component>
				<section>
					<id root="003A46B1-C116-F6C6-8D39-FF92DCEF11FE"/>
					<code code="42232-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Precautions section"/>
					<title mediaType="text/x-hl7-title+xml">PRECAUTIONS</title>
					<text>
						<list listType="ordered">
							<item>
								<paragraph>The cardiovascular status of the patient should be carefully
evaluated before rapidly administering mannitol since sudden expansion of
the extracellular fluid may lead to fulminating congestive heart failure.</paragraph>
							</item>
							<item>
								<paragraph>Shift of sodium-free intracellular fluid into the extracellular
compartment following mannitol infusion may lower serum sodium concentration
and aggravate pre-existing hyponatremia.</paragraph>
							</item>
							<item>
								<paragraph>By sustaining diuresis, mannitol administration may obscure
and intensify inadequate hydration or hypovolemia.</paragraph>
							</item>
							<item>
								<paragraph>Electrolyte-free mannitol solutions should not be given conjointly
with blood. If it is essential that blood be given simultaneously, at least
20 mEq of sodium chloride should be added to each liter of mannitol solution
to avoid pseudoagglutination.</paragraph>
							</item>
							<item>
								<paragraph>When exposed to low temperatures, solutions of mannitol may
crystalize. If crystals are observed, the container should be warmed to redissolve,
then cooled to body temperature before administering. See NOTE under HOW SUPPLIED.
When infusing 20% or 25% mannitol concentrations, the administration set should
include a filter. Do not infuse mannitol solution if crystals are present.</paragraph>
							</item>
							<item>
								<paragraph>Do not administer unless solution is clear and container
is undamaged. Discard unused portion. Do not administer Mannitol 25% if the
Fliptop vial seal is not intact.</paragraph>
							</item>
						</list>
					</text>
					<effectiveTime value="20060608"/>
					<component>
						<section>
							<id root="C71E4E91-DF31-7ECD-80B3-F1B7751FC8CD"/>
							<code code="34083-6" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Carcinogenesis, Mutagenesis, Impairment of Fertility:</title>
							<text>
								<paragraph>Studies with solutions from flexible plastic containers have
not been performed to evaluate carcinogenic potential, mutagenic potential
or effects on fertility.</paragraph>
							</text>
							<effectiveTime value="20060608"/>
						</section>
					</component>
					<component>
						<section>
							<id root="298F56F3-661B-ACE4-DDD5-B9AC07F7BF20"/>
							<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Pregnancy section"/>
							<title mediaType="text/x-hl7-title+xml">Pregnancy Category C.</title>
							<text>
								<paragraph>Animal reproduction studies have not been conducted with
mannitol injection. It is also not known whether mannitol injection can cause
fetal harm when given to a pregnant woman or can affect reproduction. Mannitol
injection should be given to a pregnant woman only if clearly needed.</paragraph>
							</text>
							<effectiveTime value="20060608"/>
						</section>
					</component>
					<component>
						<section>
							<id root="191813A9-B998-7427-0304-10563E2E268F"/>
							<code code="34080-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="NURSING MOTHERS SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Nursing Mothers:</title>
							<text>
								<paragraph>Caution should be exercised when solutions from flexible
plastic containers are administered to a nursing mother.</paragraph>
							</text>
							<effectiveTime value="20060608"/>
						</section>
					</component>
					<component>
						<section>
							<id root="3219E5D0-3EAB-F138-2BC4-078D0123E046"/>
							<code code="34081-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PEDIATRIC USE SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Pediatric Use:</title>
							<text>
								<paragraph>See DOSAGE AND ADMINISTRATION sections. Safety and effectiveness
of solutions from flexible plastic containers in pediatric patients have not
been well established.</paragraph>
							</text>
							<effectiveTime value="20060608"/>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section>
					<id root="70E0E372-9DDC-5624-2A4C-9F30405B8F79"/>
					<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="ADVERSE REACTIONS SECTION"/>
					<title mediaType="text/x-hl7-title+xml">ADVERSE REACTIONS</title>
					<text>
						<paragraph>Adverse reactions more commonly reported during or after
the infusion of mannitol include: Pulmonary congestion, fluid and electrolyte
imbalance, acidosis, electrolyte loss, dryness of mouth, thirst, marked diuresis,
urinary retention, edema, headache, blurred vision, convulsions, nausea, vomiting,
rhinitis, arm pain, skin necrosis, thrombophlebitis, chills, dizziness, urticaria,
dehydration, hypotension, tachycardia, fever and angina-like chest pains.</paragraph>
						<paragraph>Reactions
which may occur because of the solution or the technique of administration
include febrile response, infection at the site of injection, venous thrombosis
or phlebitis extending from the site of injection, extravasation and hypervolemia.</paragraph>
						<paragraph>If
an adverse reaction does occur, discontinue the infusion, evaluate the patient,
institute appropriate therapeutic countermeasures and save the remainder of
the fluid for examination if deemed necessary.</paragraph>
					</text>
					<effectiveTime value="20060608"/>
				</section>
			</component>
			<component>
				<section>
					<id root="184303A4-1973-93F6-9354-66B6AD936963"/>
					<code code="34088-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="OVERDOSAGE SECTION"/>
					<title mediaType="text/x-hl7-title+xml">OVERDOSAGE</title>
					<text>
						<paragraph>Too rapid infusion of large amounts of mannitol will cause
a shift of intracellular water into the extracellular compartment resulting
in cellular dehydration and overexpansion of the intravascular space with
hyponatremia, congestive heart failure and pulmonary edema. Repeated doses
should not be given to patients with persistent oliguria as this can produce
a hyperosmolar state and precipitate congestive heart failure and pulmonary
edema due to volume overload. Dosage must be carefully monitored and adjusted
in accordance with the clinical situation to avoid the consequences of overdosage.
See CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and DOSAGE AND ADMINISTRATION.</paragraph>
					</text>
					<effectiveTime value="20060608"/>
				</section>
			</component>
			<component>
				<section>
					<id root="DF2DFDC5-CCB4-EEBF-A2DE-726FD8376A0C"/>
					<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
					<title mediaType="text/x-hl7-title+xml">DOSAGE AND ADMINISTRATION</title>
					<text>
						<paragraph>Mannitol I.V. (Mannitol Injection, USP) should be administered
only by intravenous infusion. The total dosage, concentration and rate of
administration should be governed by the nature and severity of the condition
being treated, fluid requirement and urinary output. The usual adult dosage
ranges from 50 to 200 g in a 24-hour period, but in most instances an adequate
response will be achieved at a dosage of approximately 100 g/24 hours. The
rate of administration is usually adjusted to maintain a urine flow of at
least 30 to 50 mL/hr. The total dose should be adjusted according to the clinical
response and adverse events (See WARNINGS). </paragraph>
						<paragraph>
							<content styleCode="italics">Test Dose:</content> A test dose of mannitol should be
given prior to instituting Mannitol I.V. therapy for patients with marked
oliguria or those believed to have inadequate renal function. In adults the
dose is 0.2 g/kg body weight. In pediatric patients the dose is 0.2 g/kg body
weight or 6 g/m<sup>2</sup> body surface area. The infusion is given as a
15% to 25% solution over a period of 3 to 5 minutes to produce a urine flow
of at least 30 to 50 mL/hour. If urine flow does not increase, a second dose
may be given; but if there is inadequate response, the patient should be re-evaluated.</paragraph>
						<paragraph>
							<content styleCode="italics">Prevention of Acute Renal Failure (Oliguria):</content> When
used during cardiovascular or other types of surgery, 50 to 100 g of mannitol
as a 5%, 10%, or 15% solution may be given. The concentration will depend
on the fluid requirements of the patient.</paragraph>
						<paragraph>
							<content styleCode="italics">Treatment
of Oliguria:</content> The usual dose to promote diuresis in oliguric patients:
Adults, 300 to 400 mg/kg of body weight (21 to 28 g for a 70 kg patient) or
up to 100 g of solution, given as a single dose (often in conjunction with
furosemide); pediatric patients, 0.25 to 2 g/kg body weight or 60 g/m<sup>2</sup> body
surface area as a 15% to 20% solution over a period of 2 to 6 hours. Doses
should not be repeated in patients with persistent oliguria.</paragraph>
						<paragraph>
							<content styleCode="italics">Reduction of Intracranial Pressure and Brain Mass:</content> In
adults a dose of 0.25 to 2 g/kg body weight as a 15% to 25% solution administered
over a period of 30 to 60 minutes; pediatric patients 1 to 2 g/kg body weight
or 30 to 60 g/m<sup>2</sup> body surface area over a period of 30 to 60 minutes.
In small or debilitated patients, a dose of 500 mg/kg may be sufficient. Careful
evaluation must be made of the circulatory and renal reserve prior to and
during administration of mannitol at the higher doses and rapid infusion rates.
Careful attention must be paid to fluid and electrolyte balance, body weight,
and total input and output before and after infusion of mannitol. Evidence
of reduced cerebral spinal fluid pressure must be observed within 15 minutes
after starting infusion.</paragraph>
						<paragraph>
							<content styleCode="italics">Reduction
of Intraocular Pressure:</content> In adults a dose of 0.25 to 2 g/kg body
weight as a 15% to 25% solution administered over a period of 30 to 60 minutes;
pediatric patients 1 to 2 g/kg body weight or 30 to 60 g/m<sup>2</sup> body
surface area over a period of 30 to 60 minutes. In small or debilitated patients,
a dose of 500 mg/kg may be sufficient. When used preoperatively, the dose
should be given one to one and one-half hours before surgery to achieve maximal
reduction of intraocular pressure before operation. </paragraph>
						<paragraph>
							<content styleCode="italics">Adjunctive Therapy for Intoxications:</content> As an
agent to promote urinary excretion of toxic substances: Adults may receive
a 5% to 25% solution for as long as indicated if urinary output remains high;
pediatric patients may receive 2 g/kg of body weight of a 5% or 10% solution.
The concentration will depend upon the fluid requirement and urinary output
of the patient. If benefits are not observed after 200 g of mannitol are administered,
discontinue the mannitol therapy. Intravenous water and electrolytes must
be given to match the loss of these substances in the urine, sweat and expired
air.</paragraph>
						<paragraph>
							<content styleCode="italics">Measurement of Glomerular
Filtration Rate (GFR):</content> 100 mL of a 20% solution (20 g) should be
diluted with 180 mL of sodium chloride injection (normal saline) or 200 mL
of a 10% solution (20&#160;g) should be diluted with 80 mL of sodium chloride
injection (normal saline). The resulting 280&#160;mL of 7.2% solution is infused
at a rate of 20 mL per minute. The urine is collected by catheter for a specific
period of time and analyzed for mannitol excreted in mg per minute. A blood
sample is drawn at the start and at the end of the time period and the concentration
of mannitol determined in mg/mL of plasma. GFR is the number of mL of plasma
that must have been filtered to account for the amount excreted per minute
in the urine. Normal clearance rates are approximately 125&#160;mL/minute
for men; 116 mL/minute for women.</paragraph>
					</text>
					<effectiveTime value="20060608"/>
					<component>
						<section>
							<id root="DFA95B3B-06C2-FCFB-D1B3-D33852320514"/>
							<code code="34073-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DRUG INTERACTIONS SECTION"/>
							<title mediaType="text/x-hl7-title+xml">Drug Interactions</title>
							<text>
								<paragraph>Additives may be incompatible. Consult with pharmacist, if
available. When introducing additives to the flexible container, use aseptic
technique, mix thoroughly and do not store.</paragraph>
								<paragraph>Do not place
25% Mannitol Injection, USP in polyvinylchloride bags; a white flocculent
precipitate may form from contact with PVC surfaces. Parenteral drug products
should be inspected visually for particulate matter and discoloration; whenever
container and solution permit. See PRECAUTIONS.</paragraph>
							</text>
							<effectiveTime value="20060608"/>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section>
					<id root="F2CE1EDB-00A8-2F39-6CE0-A244BD4DB271"/>
					<code/>
					<title mediaType="text/x-hl7-title+xml">INSTRUCTIONS FOR USE - Flexible Container</title>
					<text>
						<paragraph>
							<content styleCode="bold">To Open</content>
						</paragraph>
						<paragraph>Tear
outer wrap at notch and remove solution container. If supplemental medication
is desired, follow directions below before preparing for administration. Some
opacity of the plastic due to moisture absorption during the sterilization
process may be observed. This is normal and does not affect the solution quality
or safety. The opacity will diminish gradually.</paragraph>
						<paragraph>
							<content styleCode="bold">To Add Medication</content>
						</paragraph>
						<list listType="ordered">
							<item>
								<paragraph>Prepare additive port.</paragraph>
							</item>
							<item>
								<paragraph>Using aseptic technique and an additive delivery needle of
appropriate length, puncture resealable additive port at target area, inner
diaphragm and inject. Withdraw needle after injecting medication.</paragraph>
							</item>
							<item>
								<paragraph>The additive port may be protected by covering with an additive
cap.</paragraph>
							</item>
							<item>
								<paragraph>Mix container contents thoroughly.</paragraph>
							</item>
						</list>
						<paragraph>
							<content styleCode="bold">Preparation for Administration</content>
						</paragraph>
						<paragraph>
							<content styleCode="bold">(Use aseptic technique)</content>
						</paragraph>
						<list listType="ordered">
							<item>
								<paragraph>Close flow control clamp of administration set.</paragraph>
							</item>
							<item>
								<paragraph>Remove cover from outlet port at bottom of container.</paragraph>
							</item>
							<item>
								<paragraph>Insert piercing pin of administration set into port with
a twisting motion until the set is firmly seated. NOTE: See full directions
on administration set carton.</paragraph>
							</item>
							<item>
								<paragraph>Suspend container from hanger.</paragraph>
							</item>
							<item>
								<paragraph>Squeeze and release drip chamber to establish proper fluid
level in chamber.</paragraph>
							</item>
							<item>
								<paragraph>Open flow control clamp and clear air from set. Close clamp.</paragraph>
							</item>
							<item>
								<paragraph>Attach set to venipuncture device. If device is not indwelling,
prime and make venipuncture.</paragraph>
							</item>
							<item>
								<paragraph>Regulate rate of administration with flow control clamp.</paragraph>
							</item>
						</list>
						<paragraph>
							<content styleCode="bold">WARNING: Do not use flexible container
in series connections.</content>
						</paragraph>
					</text>
					<effectiveTime value="20060608"/>
				</section>
			</component>
			<component>
				<section>
					<id root="F02ADFC2-E6E3-2652-98F2-A4B0DE77FF37"/>
					<code/>
					<title mediaType="text/x-hl7-title+xml">INSTRUCTlONS FOR USE - Fliptop Vial</title>
					<text>
						<paragraph>Remove cover and cleanse stopper with antiseptic before use. </paragraph>
					</text>
					<effectiveTime value="20060608"/>
				</section>
			</component>
			<component>
				<section>
					<id root="8E00B559-B8EB-C0AD-A97F-10AB2733E56F"/>
					<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HOW SUPPLIED SECTION"/>
					<title mediaType="text/x-hl7-title+xml">HOW SUPPLIED</title>
					<text>
						<paragraph>Mannitol I.V. (Mannitol Injection, USP) is supplied in single-dose
containers as follows:</paragraph>
						<table frame="void">
							<caption/>
							<colgroup>
								<col/>
								<col/>
								<col/>
							</colgroup>
							<tbody>
								<tr>
									<td valign="top">
										<paragraph>
											<content styleCode="bold">List No.</content>
										</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>
											<content styleCode="bold">Conc.
%</content>
										</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>
											<content styleCode="bold">Size
(mL)</content>
										</paragraph>
									</td>
								</tr>
								<tr>
									<td valign="top">
										<paragraph>7712</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>5</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>1000 Flexible Container</paragraph>
									</td>
								</tr>
								<tr>
									<td valign="top">
										<paragraph>7713</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>10</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>1000 Flexible Container</paragraph>
									</td>
								</tr>
								<tr>
									<td valign="top">
										<paragraph>7714</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>15</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>500 Flexible Container</paragraph>
									</td>
								</tr>
								<tr>
									<td valign="top">
										<paragraph>7715</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>20</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>250 Flexible Container</paragraph>
									</td>
								</tr>
								<tr>
									<td valign="top"/>
									<td valign="top"/>
									<td align="center" valign="top">
										<paragraph>500 Flexible Container</paragraph>
									</td>
								</tr>
								<tr>
									<td valign="top">
										<paragraph>4031</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>25</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>50 Fliptop Vial</paragraph>
									</td>
								</tr>
							</tbody>
						</table>
						<paragraph>NOTE: Crystals may form in mannitol solutions especially
if the solutions are chilled. To dissolve crystals in the flexible container,
warm the unit to 70&#176;C with agitation. Heat solution by using a dry-heat
cabinet with overwrap intact. The use of a water bath is not recommended.
To dissolve the crystals in the fliptop vial, warm the bottle in hot water
at 80&#176;C and periodically shake vigorously.  25% Mannitol Injection, USP
may be autoclaved at 121&#176;C for 20 minutes at 15 psi. Remove cover from
fliptop vial and cleanse stopper with antiseptic before use. Cool to body
temperature or less before administering. When infusing 20% or 25% mannitol
concentrations, the administration set should include a filter.</paragraph>
						<paragraph>Exposure
of pharmaceutical products to heat should be minimized. Avoid excessive heat.
Protect from freezing. It is recommended that the flexible containers be stored
at room temperature (25&#176;C), however, brief exposure up to 40&#176;C does
not adversely affect the product. Store Fliptop vials at controlled room temperature,
15&#176; to 30&#176;C (59&#176; to 86&#176;F). [See USP.]</paragraph>
						<table frame="void">
							<caption/>
							<colgroup>
								<col/>
								<col/>
								<col/>
							</colgroup>
							<tbody>
								<tr>
									<td valign="top"/>
									<td valign="top"/>
									<td valign="top">
									</td>
								</tr>
								<tr>
									<td valign="top">
										<paragraph>&#169;Hospira 2004</paragraph>
									</td>
									<td align="center" valign="top">
										<paragraph>EN-0074</paragraph>
									</td>
									<td align="right" valign="top">
										<paragraph>Printed in USA</paragraph>
									</td>
								</tr>
							</tbody>
						</table>
						<paragraph>
							<content styleCode="italics">HOSPIRA, INC., LAKE FOREST,
IL 60045 USA</content>
						</paragraph>
					</text>
					<effectiveTime value="20060608"/>
				</section>
			</component>
		</structuredBody>
	</component>
</document>
